SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
LATEST POSTS
- 1
The Main 15 Applications for Efficiency and Association - 2SpaceX's 1st 'Version 3' Super Heavy Starship booster buckles under pressure during initial tests
- 3Golden Globes 2026 full nominations list: 'One Battle After Another' and 'The White Lotus' lead in film and television categories
- 4Coffee Prices Finish Higher on Brazil Cop Concerns
- 5Excelling at Cash The board: A Manual for Monetary Essentials
- Flu illness count nears 5 million, with New York City among the hardest hit
- Home Machine Basics: An Exhaustive Purchasing Guide
- Uzbekistan launches €9.46 billion green energy push, covering nation’s power needs
- Chemical leak in Oklahoma forces evacuations and leaves many ill
- Director Emerald Fennell explains why "Wuthering Heights" has quotation marks around the title
- Family-Accommodating Snow Sports Experiences
- Discovering a sense of harmony: Individual Accounts of Reflection and Care
- Independence from the rat race for Recent college grads: Systems and Tips
- Fake new headlights rule steer Australian drivers astray
